There are 2949 resources available
Defining HER2 and HER3 status: Taking a deeper dive
Presenter: Giuseppe Viale
Session: Medscape - The HER-pathway in advanced solid tumours: Advances in targeting HER2 and future prospects for HER3
Resources:
Webcast
Recent developments for the patient with HER2-positive metastatic breast cancer
Presenter: Sara Hurvitz
Session: Medscape - The HER-pathway in advanced solid tumours: Advances in targeting HER2 and future prospects for HER3
Resources:
Webcast
Targeting the HER pathway in other tumors: An evolving paradigm
Presenter: Javier Cortés
Session: Medscape - The HER-pathway in advanced solid tumours: Advances in targeting HER2 and future prospects for HER3
Resources:
Webcast
Emerging HER2-directed therapies in gastric and colorectal cancer
Presenter: Kohei Shitara
Session: Medscape - The HER-pathway in advanced solid tumours: Advances in targeting HER2 and future prospects for HER3
Resources:
Webcast
Evolving approaches in targeting HER2 in advanced NSCLC
Presenter: Egbert Smit
Session: Medscape - The HER-pathway in advanced solid tumours: Advances in targeting HER2 and future prospects for HER3
Resources:
Webcast
Chair’s welcome and introductions
Presenter: Neal Shore
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Exploring molecular heterogeneity in prostate cancer - prevalence and clinical significance
Presenter: Neal Shore
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Dissecting the clinical data for PARP inhibitors in metastatic castrate resistant prostate cancer
Presenter: Joaquin Mateo
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Considerations for the approach to HRRm testing in prostate cancer
Presenter: Alexander Wyatt
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Panel discussion
Presenter: Alexander Wyatt
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast